Journal for ImmunoTherapy of Cancer · 2023 · 73 citations · 29 references
Life SciencesImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsMacrophage BiologyTumor Immune MicroenvironmentTumor-associated MacrophagesCancer-associated ImmunosuppressionCancer-associated MacrophagesImmunosuppressive MicroenvironmentMacrophage ImmunometabolismMacrophage MetabolismMalignant Pleural EffusionSingle-cell Profiling Of MacrophagesSingle-cell Rna Sequencing
Background Although immune checkpoint blockade (ICB) therapy has shown remarkable benefits in cancers, a subset of patients with cancer exhibits unresponsiveness or develop acquired resistance due to the existence of abundant immunosuppressive cells. Tumor-associated macrophages (TAMs), as the dominant immunosuppressive population, impede the antitumor immune response; however, the underlying mechanisms have not been fully elucidated yet. Methods Single-cell RNA sequencing analysis was performed to portray macrophage landscape and revealed the underlying mechanism of component 1q (C1q) + TAMs. Malignant pleural effusion (MPE) of human and mouse was used to explore the phenotypes and functions of C1q + TAMs. Results C1q + TAMs highly expressed multiple inhibitory molecules and their high infiltration was significantly correlated with poor prognosis. C1q + TAMs promote MPE immunosuppression through impairing the antitumor effects of CD8 + T cells. Mechanistically, C1q + TAMs enhance fatty acid binding protein 5 (FABP5)-mediated fatty acid metabolism, which activate transcription factor peroxisome proliferator-activated receptor-gamma, increasing the gene expression of inhibitory molecules. A high-fat diet increases the expression of inhibitory molecules in C1q + TAMs and the immunosuppression of MPE microenvironment, whereas a low-fat diet ameliorates these effects. Moreover, FABP5 inhibition represses the expression of inhibitory molecules in TAMs and tumor progression, while enhancing the efficacy of ICB therapy in MPE and lung cancer. Conclusions C1q + TAMs impede antitumor effects of CD8 + T cells promoting MPE immunosuppression. Targeting C1q + TAMs effectively alleviates the immunosuppression and enhances the efficacy of ICB therapy. C1q + TAMs subset has great potential to be a therapeutic target for cancer immunotherapy.
29
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui et al. · New England Journal of Medicine · 2015 · 6.2K citations · Full text
Medicine, Oncology, Pharmacology +17
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Scott Antonia, Augusto Villegas, Davey B. Daniel et al. · New England Journal of Medicine · 2018 · 2.8K citations · Full text
Medicine, Oncology, Pharmacotherapy +17
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Sydney R. Gordon, Roy L. Maute, Ben W. Dulken et al. · Nature · 2017 · 2.3K citations · Full text
Life Sciences, Immunology, Oncology +16
Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
Qiming Zhang, Yao He, Nan Luo et al. · Cell · 2019 · 1.7K citations · Full text
Medicine, Immunology, Oncology +14
Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer
Lei Zhang, Ziyi Li, Katarzyna M. Skrzypczynska et al. · Cell · 2020 · 1.6K citations · Full text
Medicine, Cell Biology, Oncology +16